Synonyms: HuZAF
Compound class:
Antibody
|
References |
1. Baker KF, Isaacs JD. (2018)
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. Ann Rheum Dis, 77 (2): 175-187. [PMID:28765121] |
2. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S et al.. (2006)
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut, 55 (8): 1131-7. [PMID:16507585] |
3. Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN et al.. (2010)
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis, 16 (2): 233-42. [PMID:19637334] |
4. Vasquez M, Landolfi NF, Tsurushita N, Queen CL. (2001)
Humanized antibodies to γ-interferon. Patent number: US6329511B1. Assignee: Protein Design Labs Inc. Priority date: 01/12/1998. Publication date: 11/12/2001. |